analyst's review.I am keeping a close eye on the RSI .. possibly a dead cat bounce coming ?
Here's the first paragraph of RJ analyst's take on the latest activity of PROF.
sorry the formatting won't copy over.
RECOMMENDATION Profound Medical (PROF-NASDAQ, SB1) reported 3Q21 results last night with a wide miss on Rev. ($2.5 mln vs. $3.1 mln RJe; $3.5 mln consensus; see our Pre-3Q21 expectations).
So, with this Q’s disappointing revenue, we have taken a moment to reflect on our view of PROF. We have always believed the right way to think about this stock is on an 18-month time horizon, certainly not quarter-to-quarter; however, while our conviction in PROF’s fundamentals remain undiminished, we do owe a mea culpa on the fact that we got the timing of our call wrong by ~1 year(explanationonpg.2). As such, we take this opportunity to adjust our revenue estimates to what we believe is a reasonable baseline that PROF should meet—if not, beat—going forward. As such, we cut our 2022 EV/Rev.-driven target price to $28, but, maintaining our focus on PROF’s exceedingly strong fundamentals, we reiterate our Strong Buy ratin